Orforglipron Shows Significant Weight Loss and Safety Benefits in Adults 65 and Older, New Analysis Finds

A sub-group analysis of the ATTAIN-1 and ATTAIN-2 trials finds that orforglipron produced significant reductions in body weight and HbA1c in adults aged 65 and older, with a safety profile consistent with younger populations.

WeightControl.com Interview with:
Deborah B. Horn, DO, MPH, FOMA
Medical Director for Center of Obesity Medicine and Metabolic Performance
McGovern Medical School
UTHealth Houston, Texas

A new sub-group analysis of two major clinical trials examines how the oral GLP-1 medication orforglipron performs in adults aged 65 and older — with encouraging findings on both efficacy and safety. Continue reading “Orforglipron Shows Significant Weight Loss and Safety Benefits in Adults 65 and Older, New Analysis Finds”

GLP-1 Medications and Long-Term Health Outcomes: What Real-World Data Reveals About Stopping Treatment

Real-world data shows that patients who stay on GLP-1 medications are more likely to maintain meaningful weight loss and avoid serious health complications — while those who stop treatment face greater risk.

WeightControl.com Interview with:
John Wilding DM FRCP
Professor of Medicine & Honorary Consultant Physician
Department of Cardiovascular and Metabolic Medicine
Institute of Life Course and Medical Sciences
Clinical Sciences Centre
Aintree University Hospital
Liverpool, United Kingdom

A large real-world analysis of electronic health records and health claims data in the United States examines what happens to patients prescribed GLP-1 based treatments — and what the consequences are when they stop.

Continue reading “GLP-1 Medications and Long-Term Health Outcomes: What Real-World Data Reveals About Stopping Treatment”

ECO24: Ideal Weight For Patients with Diabetes May Vary with Age

For older individuals who are moderately overweight , maintaining rather than reducing weight may be a more practical goal.

WeightControl.com Interview with:
Dr Shaoyong Xu
Xiangyang Central Hospital
Affiliated Hospital of Hubei University of Arts and Science
Xiangyang, China

WeightControl.com:  What is the background for this study? 

Response: In previous studies, the obesity paradox has been observed, where overweight and obese individuals with cardiovascular disease have better outcomes compared to their slim counterparts with the same disease. The global prevalence of diabetes is steadily increasing year by year.

In this era of population growth and aging, the question arises as to whether obesity or overweight can be beneficial in improving survival rates for older individuals with diabetes. This topic holds significant relevance due to the potential implications it has on weight management strategies for older adults. If overweight does not pose an increased risk of cardiovascular mortality, it may suggest that older individuals are not necessarily required to strive for weight loss in order to achieve so-called normal values. Moreover, inappropriate weight loss and being underweight could potentially elevate the risk of cardiovascular events, myocardial infarction, cerebral infarction, and all-cause mortality.

ECO24: Tirzepatide Found Effective for Weight Loss Despite Duration of Obesity

Tirzepatide is a once weekly GIP and GLP-1 receptor agonist while semaglutide was a once weekly GLP-1 receptor agonist

WeightControl.com Interview with:
Giovanna Muscogiuri, MD, PhD
Assistant Professor
Endocrinology Unit
University Federico II
Naples, Italy

WeightControl.com:  What is the background for this study? 

Response: The study was a subgroup analysis of SURMOUNT 1-4 aiming to investigate if tirzepatide was effective in terms of percent body weight change, proportions achieving weight loss targets of 5, 10, 15, 20, and 25% and change in waist circumference in subjects with different duration of obesity.

After Bariatric Surgery, Women Advised to Wait At Least Two Years to Conceive

After bariatric surgery there is a rapid weight loss that may impair an adequate weight gain during pregnancy and may also be associated with nutritional deficiencies

WeightControl.com Interview with:
Dr Ana Carreira and Dr Bárbara Araújo
Department of Endocrinology and Metabolism
Centro Hospitalar e Universitário de Coimbra
Coimbra, Portuga

WeightControl.com:  What is the background for this study? 

Response: Bariatric surgery is increasingly common in women of reproductive age and reduces the risk of obesity-related comorbidities in pregnancy. However, women after bariatric surgery have an increased risk of having a baby who is underweight (small for gestational age, SGA). A shorter bariatric surgery-to-conception interval (BSCI) has been one of the factors associated with a higher risk of SGA neonates, and, as a result, women are generally advised to wait at least 12 months after bariatric surgery before trying to conceive. However, the optimal bariatric surgery-to-conception interval is yet to be determined, and current recommendation differ among scientific societies, with some advocating a minimum of 12months and others 18 or 24 months.